Trinity Delta Lighthouse: HUTCHMED
Trinity Delta view: HUTCHMED’s strategy to accelerate its path to profitability and bring first-in-class and best-in-class targeted therapies to the market globally has been boosted by the Takeda fruquintinib partnership. This broadens fruquintinib’s development and commercial potential and gives HUTCHMED greater bandwidth to further maximise the commercial traction underway in China, and to progress its late-stage pipeline. Our last published HUTCHMED valuation was $5.51bn ($31.89 per ADS), £4.6bn and HK$43.1bn (531p or HK$49.83 per share), which was pre the Takeda deal and does not reflect FY22 results.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.